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Abstract
Amyotrophic lateral sclerosis (ALS) is a paralyzing disorder characterized by the progressive degeneration and
death of motor neurons and occurs both as a sporadic and familial disease. Mutant SOD1 (mtSOD1) in motor
neurons induces vulnerability to the disease through protein misfolding, mitochondrial dysfunction, oxidative
damage, cytoskeletal abnormalities, defective axonal transport- and growth factor signaling, excitotoxicity, and
neuro-inflammation.
Melittin is a 26 amino acid protein and is one of the components of bee venom which is used in traditional
Chinese medicine to inhibit of cancer cell proliferation and is known to have anti-inflammatory and anti-arthritic
effects.
The purpose of the present study was to determine if melittin could suppress motor neuron loss and protein
misfolding in the hSOD1
G93A mouse, which is commonly used as a model for inherited ALS. Meltittin was injected
at the ‘ZuSanLi’ (ST36) acupuncture point in the hSOD1
G93A animal model. Melittin-treated animals showed a
decrease in the number of microglia and in the expression level of phospho-p38 in the spinal cord and brainstem.
Interestingly, melittin treatment in symptomatic ALS animals improved motor function and reduced the level of
neuron death in the spinal cord when compared to the control group. Furthermore, we found increased of
a-synuclein modifications, such as phosphorylation or nitration, in both the brainstem and spinal cord in
hSOD1
G93A mice. However, melittin treatment reduced a-synuclein misfolding and restored the proteasomal
activity in the brainstem and spinal cord of symptomatic hSOD1
G93A transgenic mice.
Our research suggests a potential functional link between melittin and the inhibition of neuroinflammation in an
ALS animal model.
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Background
Amyotrophic lateral sclerosis (ALS) is a rapidly progres-
sing and invariably lethal neurodegenerative disease
caused by the selective death of lower neurons in the
spinal cord and upper motor neurons, and resulting in
the paralysis of voluntary muscles [1]. The familial and
sporadic forms of the disease are clinically indistinguish-
able and have been proposed to share a common patho-
genesis [1]. Mutations in Cu/Zn superoxide dismutase
(SOD1) account for approximately 20% of the cases of
the inherited form of ALS (FALS) and represent a major
known cause of the disease. Transgenic hSOD1
G93A
mice, which overexpress mutant hSOD1
G93A,d e v e l o p
the cardinal symptoms of ALS in humans, including
muscle paralysis and atrophy [2]. Although the exact
molecular mechanisms underlying mutant SOD1
mediated motor neuron degeneration are unclear, the
proposed pathophysiological mechanisms of ALS
include mitochondrial dysfunction [3], glutamate
excitotoxicity [4], disrupted axonal transport [5], and
inflammation [6].
Bee venom (BV) is extracted from honeybees and is
known as apitoxin. It is used in traditional medicine to
reduce inflammation in chronic rheumatoid arthritis and
osteoarthritis [7]. Furthermore, we have previously inves-
tigated the effects of BV on motor function in a neuroin-
flammation-related neurodegenerative disease and have
demonstrated that BV has anti-neuroinflammatory
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G93A
mice [8].
BV contains a number of bioactive compounds,
including histamine, epinephrine, free amino acids,
enzymes (e.g., phospholiphase 2; PLA2), and a variety of
peptides (e.g., melittin and apamin) [9]. Melittin is a
strongly basic, 26-amino acid polypeptide that constitu-
tes 40 to 60% of dry whole honeybee venom, and the
peptide has various biological, pharmacological, and tox-
icological actions, including strong surface activity on
cell lipid membranes hemolyzing antibacterial, and anti-
fungal activity [10-12], and antitumor properties [13].
Melittin is also thought to be the major biologically
active substance in BV that induces the anti-nociceptive
and anti-inflammatory effects observed when BV is
applied to an acupoint [9]. In addition, the direct injec-
tion of melittin into the rat ventral tegmental area
causes sensitization to subsequent cocaine administra-
tion, as evidenced by increased cocaine-induced locomo-
tor activity, stereotypy, and dopamine release in the
nucleus accumbens [14].
However, the effects of melittin on neuroinflammation
are still not clear, and the cellular mechanisms that reg-
ulate post-translational modification in hSOD1
G93A mice
remain to be clarified.
To determine the single bioactive element of BV
responsible for the observed anti-neuroinflammatory
effects in animal models of ALS, we investigated the
effects of melittin in symptomatic hSOD1
G93A mice.
Melittin treatment was sufficient to improve motor
activity compared to age-matched hSOD1
G93A mice, and
the peptide inhibited the increased neuroinflammation
that is responsible for neuronal death. Furthermore, we
found that the post-translational modification of a-synu-
clein is regulated by melittin treatment and that it is
mediated by an increase in Heat Shock Protein70
(HSP70) expression and increased proteasome activity.
T h e s ef i n d i n g ss u g g e s tap o t e n t i a lf u n c t i o n a ll i n k
between melittin and the inhibition of neuroinflamma-
tion in an animal model of ALS and could have impor-
tant implications for the treatment of Parkinson’s
disease (PD) and ALS.
Methods
Animals
hSOD1
G93A mice were handled in accordance with the
National Institutes of Health guidelines (Bethesda, MD).
The protocols were approved by the Institutional Ani-
mal Care and Use Committees of the Korea Institute of
Oriental Medicine. Hemizygous transgenic B6SJL mice
carrying a glycine- to-alanine mutation at the 93
rd
codon of the cytosolic Cu/Zn superoxide dismutase
gene (hSOD1
G93A) were originally obtained from the
Jackson Laboratory (Bar Harbor, ME). Transgenic mice
were identified by PCR as described previously [39]. All
mice were kept in standard housing with free access to
water and standard rodent chow.
Melittin treatment
Melittin was purchased from Sigma (St. Louis, MO) and
diluted with saline. Melittin (0.1 μg/g) was subcuta-
neously injected bilaterally into 98-day-old male
hSOD1
G93A transgenic mice (hSOD1
G93A-MT, n= 11) at
the Zusanli (ST36) acupoint, which is known to mediate
anti-inflammatory effects [40]. The male mice were trea-
ted with melittin twice a week. The ST36 point is anato-
mically located 5 mm below and lateral to the anterior
tubercle of the tibia in regard to the human acupoint
landmark and a mouse anatomical reference [41]. Age-
matched control animals were injected bilaterally and
subcutaneously with an equal volume of saline at the
ST36 acupoint (hSOD1
G93A, n= 10).
Behavioral analysis (rotarod test)
Mice for this study were trained for 1 week prior to
melittin treatment in order for them to adapt to the
apparatus. After training of the hSOD1
G93A mice, their
basal motor performance was measured with a rotarod
apparatus (Ugo, Basil, Italy). Motor coordination was
assessed as described previously [8].
Life span study
For lifespan analysis, 98-day-old male hSOD1
G93A mice
were divided into two groups: saline-treated
hSOD1
G93A mice (n= 11) and melittin treated
hSOD1
G93A mice (n= 11). We defined “death” that as
the day on which the mouse stopped breathing. The
significance of the difference in the survival of the
treated mice was measured with Kaplan-Meier survival
curves using Prism 5.0 software (GraphPad Software,
CA, USA) and Sigmaplot 10 software (Systat Software,
CA, USA). Values were analyzed by a one-way
ANOVA followed by a Dunn’s multiple-comparison
test.
Tissue preparation and Immunohistochemistry
hSOD1
G93A mice were deeply anesthetized with pento-
barbital 18 days after the initiation of the melittin or sal-
ine treatment and perfused with phosphate -buffered
saline (PBS). The spinal cord and brain were removed
and fixed in 4% paraformaldehyde overnight at 4°C,
transferred to 30% sucrose in PBS, and then frozen at
-70°C. Preparation of the spinal cord and brainstem
were performed as described previously [8]. Briefly, the
spinal cord and brainstem were embedded in OCT com-
pound cut on a cryostat into coronal slices (40 μm
thickness). Selected free-floating sections were treated
with 0.6% H2O2 to inactivate endogenous peroxidases
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dilution) or anti-ubiqutin (DAKO, Glostrup, Denmark;
1:2000 dilution). After incubation with primary antibo-
dies, the sections were washed with PBST (0.3% Tween
20 in PBS) and incubated with a 1:1000 dilution of the
secondary antibody. For visualizing, the ABC Elite
kit (Vector Laboratories: Burligame, CA, USA) and 3,
3’-diaminobenzidine (DAB)/H2O2 s u b s t r a t ew e r eu s e d .
Immunostained spinal cord and brainstem sections
were observed with a light microscope (Olympus,
Tokyo, Japan). Immunoreactive cells were counted
using an image analysis software package (IMT
i-solution, NJ, USA).
Western blot analysis
Eighteen days after the treatment of the melittin or
saline treatment, the brainstem and spinal cords were
dissected and homogenized in RIPA buffer (50 mM
Tris-Cl pH 7.4, 1% NP-40, 0.1% SDS, and 150 mM
NaCl) containing a protease inhibitor cocktail (Calbio-
chem, CA, USA). Homogenized tissues were centrifuged
at 14,000 rpm for 20 min at 4°C. The protein concen-
tration was determined using a BCA assay (Pierce, IL,
USA). Samples denatured with sodium dodecyl sulfate
(SDS) sampling buffer were seperated through SDS-
polyacrylamide gel electrophoresis (PAGE) and trans-
ferred to a nitrocellulose membrane for western blot.
For detection of target proteins, the menbranes were
blocked with 5% non-fat milk in TBS and then incu-
bated with the various primary antibodies: anti-tubulin
(Abcam, Cambridge, UK), anti-p38 (Cell Signaling
Technologies), anti-phospho-p38 (Cell Signaling Tech-
nologies), anti-Iba-1 (Wako, Osaka, Japan), anti-TNF-a
or anti-ubiquitin (DAKO, Carpinteria, CA). The blots
were then probed with peroxidase-conjugated antibodies
(Santa Cruz Biotechnology, CA, USA) and visualized by
using enhanced chemiluminescence (ECL) reagents
(Amersham Pharmacia, NJ, USA). An LAS-3000 image
analyzer was used for detecting immunoblotted bands
(Fujifilm, Tokyo, Japan).
Proteasomal activity assay
Whole lysates from the spinal cord and brainstem were
prepared with lysis buffer containing 20 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 5 mM EDTA, and 0.1% SDS and
supplemented with 10 mg/ml of aprotinin, 1 mmol/ml
PMSF, and 10 mg/ml of leupeptin. The protein concen-
tration was determined using a BCA protein assay kit
(Interchim, Paris, France). Proteasome activity was per-
formed using a 20S Proteasome Activity Assay kit (Che-
micon Inc., CA, USA). An AMC fluorogenic standard
curve was measured by diluting the reconstituted AMC
standard in the concentration range of 0.125 -12.5 μM.
Tissue lysates were mixed with a proteasome substrate
(Suc-LLVY-AMC) and assay buffer (250 mM HEPES,
pH 7.5, 5 mM EDTA, 0.5% NP-40, and 0.01% SDS) in a
96-well fluorometer plate. For positive control assays,
20S proteasome positive control was diluted 1:10 in
assay buffer (25 mM HEPES, pH 7.5, 0.5 mM EDTA,
0.05% NP-40, and 0.001% SDS). The reaction mixture
was incubated at 37°C for 2 hours, and the fluorescence
was read using a 350/450 nm filter set in a fluorometer.
Statistical analysis
All data were analyzed using GraphPad Prism 5.0
(GraphPad Software, CA, USA) and are presented as the
mean ± SEM where inducated. A t-test was used to
compare the significance of the differences of the immu-
noblotting and immunohistochemical data between the
melittin-treated mice and the age-matched untreated
hSOD1
G93A mice.
Results
Melittin treatment increases motor performance in
symptomatic hSOD1
G93A transgenic mice
To determine the effects of melittin on the motor
function and survival of hSOD1
G93A mice, melittin (0.1
μg/g) was subcutaneously injected bilaterally at ST36
(Figure 1). In the rotarod behavioral test, which
Figure 1 The effect of melittin treatment on motor activity
in symptomatic hSOD1
G93A mice. 14-week-old (98 day old)
hSOD1
G93A mice were bilaterally treated with saline (n= 10/group,
circles) or 0.1 μg/ml melittin (n= 11/group, squares) subcutaneously
at ST36. Based on the results of the rotarod behavioral test for the
measurement of motor function, the motor function of melittin-
treated hSOD1
G93A mice significantly improved compared with
saline-treated hSOD1
G93A 7 days after the initiation of melittin
treatment. The values represent as the comparison with melittin-
treated hSOD1
G93A transgenic mice (**p<0.001). S: second, Con:
saline-treated hSOD1
G93A, MT: melittin-treated hSOD1
G93A
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G93A
mice (n = 11) displayed a 1.7-fold increase in motor
function 7 days after treatment with melittin (Figure 1).
Furthermore, melittin-treated hSOD1
G93A mice (n = 11)
showed a 2.8-fold improvement in motor activity 10
days after melittin treatment compared to age-matched
control mice (n = 10) (Figure 1). Disease onset and
paralysis, which is a pathological symptom of hOD1
G93A
mice, was delayed 1 week in melittin-treated mice com-
pared to saline-treated hSOD1
G93A mice. Given that
melittin treatment improved motor activity and delayed
disease onset in hSOD1
G93A transgenic mice, we next
compared the survival rate using Kaplan-Meier survival
analyses. The median survival of the melittin-treated
group (132 ± 3.2 days, n = 11) was not significantly dif-
ferent from that of control group (129 ± 2.5 days, n = 11)
(Figure 2). It indicates that the melittin treatment does
not influence the lifespan of hSOD1
G93A mice. However,
melittin-treated hSOD1
G93A transgenic mice showed
delayed disease onset compared to age-matched saline-
treated controls (data not shown). Overall, these results
indicate that melittin treatment delays the onset of motor
dysfunction and disease progression but is not sufficient
for increasing the lifespan of hSOD1
G93A mice.
Melittin reduces neuroinflammation in symptomatic
hSOD1
G93A transgenic mice
Because we have previously demonstrated that treatment
with BV treatment reduces microglial activation and
neuroinflammation [8], we analyzed the effects of melit-
tin, a component of BV, on microglial activation in
symptomatic hSOD1
G93A mice. As shown in Figure 3A,
Iba-1 expression, which was used as a marker of micro-
glial activation, was significantly decreased in both the
brainstem and spinal cord of melittin-treated
hSOD1
G93A mice. In immuohistochemical study, it
confirmed that melittin treatment reduced Iba-1 immu-
noreactivity largely confined to the facial nucleus of the
brain stem and the anterior horn of the lumbar spinal
cord (L4) in symptomatic hSOD1
G93A mice (Figure 3G -
Figure 3J). To further assess the effect of melittin on
Figure 2 The effect of melittin on the survival rate of
hSOD1
G93A mice. Melittin treatment did not alter the survival of
hSOD1
G93A mice, as shown by a Kaplan-Meyer analysis. Melittin-
treated (0.1 μg/g/98day, n = 11) or saline-treated transgenic
hSOD1
G93A mice (n = 11) had comparable median lifespans (132 ±
3.2 days and 129 ± 2.5 days, respectively). Con: saline- treated mice,
MT: melittin -treated mice
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Figure 3 Western blot and immunohistochemical detection of
anti-neuroinflammatory events in the brainstem and spinal
cord. The western blot image is representative of three
independent experiments. A representative blot of Iba-1 (A) or TNF-
a (B) demeonstrates a significant reduction in the expression of
these molecules in the brainstem and spinal cord of melittin-treated
hSOD1
G93A mice. The expression of MAP2 (a neuron marker) is
dramatically increased in both the brainstem and spinal cord of
melittin-treated hSOD1
G93A mice compared with saline-treated
hSOD1
G93A mice (C). a-tubulin was used for loading control. The
activation of p38 is increased in the brainstem and spinal cord of
hSOD1
G93A mice, but melittin-treated hSOD1
G93A mice showed
reduced expression of phospho-p38 (E). The expression of p38 was
used as a comparison for the expression of activated phospho-p38.
Selected free-floating fifth spinal cord or brainstem section (40 μm)
from saline- (n= 3) or melittin-treated hSOD1
G93A mice (n= 4) was
stained with an anti-Iba-1. The immunohistochemical study of Iba-1
in the facial nucleus of the brainstem and the anterior horns of the
lumbar (L4) spinal cord confirmed that melittin treatment reduced
the number of Iba-1-expressing cells in the hSOD1
G93A mice
compared to age-matched control mice (G-J). The large box
presents higher magnification views of the small box in the facial
nucleus region of the brainstem in control hSOD1
G93A mice (G).
Scale bars = 200 μm (G, H). Scale bars = 100 μm (I, J). MT: melittin,
BS: brainstem, SP: spinal cord.
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release of the pro-inflammatory cytokine TNF-a,
western blots were performed using an anti-TNF-a anti-
body The expression of TNF-a was dramatically
reduced in the brainstem and spinal cord of melittin-
treated hSOD1
G93A mice compared to age-matched con-
trols (Figure 3B). Interestingly, melittin treatment
increased the expression of the neuronal cell marker
MAP2 in both the brainstem and lumbar spinal cord of
symptomatic hSOD1
G93A mice (Figure 3C).
p38 kinase activity is strongly associated with motor
neuron degeneration in this animal model of ALS [15].
Given the previous reports of Yang et al. on the effect
of BV on p38 activation [8], we examined the effect of
m e l i t t i no np 3 8k i n a s ea c t i v i t yi ns y m p t o m a t i c
hSOD1
G93A mice. Phosphorylation of p38 was reduced
in the brainstem and spinal cord of hSOD1 transgenic
mice following treatment with melittin (Figure 3E).
These findings suggest that melittin, a component of
BV, has a critical role in inhibiting neuroinflammation
in symptomatic hSOD1
G93A mice, which results in the
attenuation of motor neuron loss.
Melittin inhibits a-synuclein modification and increases
the expression of heat shock protein 70
As a synaptic protein, a-synuclein is a pathological
marker for PD and has been implicated in several
neurodegenerative diseases, including multiple system
atrophy (MSA) [16]. In familial ALS patients, a-synu-
clein is detected in the glial white matter and glial gray
matter [17]. To explore the expression and modification
of a-synuclein in symptomatic hSOD1
G93A mice, we
performed a biochemical study of the brainstem and
spinal cord of mice with ALS. Higher molecular weight
bands (>17 kDa), indicative modified of a-synuclein
were observed in the brainstem and spinal cord of
hSOD1
G93A mice (Figure 4A). The expression of modi-
fied a-synuclein, including Ser129-phosphorylated and
nitrated a-synuclein was significantly increased in the
brainstem and spinal cord of hSOD1
G93A mice (Figure
4B, C). However, melittin-treated hSOD1
G93A mice
demonstrated reduced expression of post-translationally
modified a-synuclein in the brainstem and lumbar
spinal cord (Figure 4B, C). To ascertain the mechanism
underlying the decreased modification of a-synuclein
following melittin treatment of symptomatic hSOD1
G93A
mice. We examined the expression of HSP 70 in the
brainstem and spinal cord of melittin-treated
hSOD1
G93A mice compared to age-matched controls. As
shown in Figure 4D, we observed increased expression
of HSP70 in the brainstem and spinal cord of melittin-
treated hSOD1
G93A mice. Importantly, HSP70 is known
to reduce a-synuclein-mediated toxicity and aggregation
[18,19]. To determine whether melittin regulates the
ubiquitin/proteasome system (UPS) in hSOD1
G93A mice,
we investigated ubiquitin expression in the brainstem
and spinal cord of saline- and melittin-treated mice. As
expected, melittin treatment significantly reduced the
number of ubiquitin-expressing cells in both the brain-
stem (Figure 5A, B) and ventral horn of spinal cord in
symptomatic hSOD1
G93A mice (Figure 5C, D). Further-
more, we confirmed a-synuclein inclusions were coloca-
lized with ubiquitin in motor neurons of ventral horn of
spinal cord in symptomatic hSOD1
G93A (Figure 5E-5G).
These findings suggest that melittin treatment may
affect UPS function, which in turn, regulates the
post-translational modification (e.g., phosphorylation
and ubiquitination) of pathological proteins.
Reduced proteasome activity is restored in hSOD1
G93A
mice following treatment with melittin
To assess whether the observed reduction in total pro-
teasome activity in the brainstem and lumbar spinal
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Figure 4 The Effect of melittin treatment on the post-
translation modification of a-synuclein in symptomatic
hSOD1
G93A mice. The western blot image is representative of three
independent experiments. Higher molecular weight forms of a-
synuclein were expressed in spinal cord of hSOD1
G93A mice, but this
expression was reduced following metlittin treatment (A). The level
of nitrated (B) and phosphorylated a-synuclein (C) was decreased in
the brainstem and spinal cord of melittin-treated mice. The
expression of HSP70 was increased by melittin treatment in the
brainstem and spinal cord in hSOD1
G93A mice (D). HSC70 (E) and
tubulin (F) were used as loading controls.
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G93A mice was the result of a decreased
number of proteasomes or a reduced proteasomal activ-
ity, 20S proteasome activity was examined using a pro-
teasome activity assay with a fluorescent substrate. Total
proteasome activity (nmol/min/mg) of the brainstem or
lumbar spinal cord in symptomatic hSOD1
G93A mice
showed each 1.8- fold reduction compared to age-
matched non-transgenic mice (Figure 6A, B). In addi-
tion, melittin treatment did not significantly affect total
proteasome acitivity in non-transgenic mice (Figure 6A).
However, proteasome activity following melittin treat-
ment was restored a 50% in the brainstem and a 40% in
the lumbar spinal cord of symptomatic hSOD1
G93A
mice (Figure 6B). These results suggest that reduced
proteasome activity results in an increase in the modifi-
cation of pathological proteins, such as a-synuclein, and
that melittin treatment can inhibit the loss of protea-
some activity in neurodegenerative diseases.
Discussion
To improve the treatment of amyotrophic lateral sclero-
sis (ALS) and to reduce pain and extend the lifespan of
afflicted patients, it is important to find molecular mar-
kers for the underlying pathological mechanisms of this
disease. Pathological mechanisms involved in ALS may
include protein misfolding, mitochondrial dysfunction,
oxidative damage, glutamate excitotoxicity, and neuroin-
flammation. We recently demonstrated that bee venom
(BV) attenuated neuroinflammation and improved
motor performance in a symptomatic animal model of
ALS. To determine the critical bioactive compounds of
BV critical for anti-neuroinflammation, we studied the
effects of melittin, a protein that makes up 40 to 50% of
BV, in symptomatic hSOD1
G93A mice. We found that
administering melittin improved motor activity in these
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Figure 5 Co-localization of a-synuclein and ubiquitin in
anterior horns of the lumbar (L4) spinal cord in hSOD1
G93A
mice. Ubiquitin immunoreactivity (IR) is significantly reduced in the
facial nucleus of the brainstem from melittin-treated hSOD1
G93A
mice (A, B). Scale bar = 200 μm (A, B). In the anterior horn of the
spinal cord, the number of ubiquitin-expressing cells was increased
in hSOD1
G93A mice, but this was reduced by treatment with melittin
(C, D). Scale bar = 100 μm (C, D). a-synuclein inclusions (E) were
colocalized with ubiquitin (F) in motor neuron of the lumbar (L4)
spinal cord in hSOD1
G93A mice (G). Arrow head indicates double-
labelled cells. Scale bar = 50 μm (E-G). MT: melittin, BS: brainstem,
SP: spinal cord.
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Figure 6 Melittin treatment restores proteasome activity in the
brainstem and spinal cord of symptomatic hSOD1
G93A
transgenic mice. Proteasome activity was not changed by melittin
treatment in the brainstem and spinal cord of non-transgenic mice
(n = 3, A). Melittin treatment was increased proteasome activity in
the brainstem and spinal cord of hSOD1
G93A mice (n = 3) compared
to age-matched hSOD1
G93A mice (n = 3, B). NS: no significance,
*p<0.05, **p<0.001
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untreated animals; melittin administration decreased
microglial activity and the expression of the pro-inflam-
matory factor TNF-a. We also observed that melittin
alleviated post-translational modification of a-synuclein
and restored proteasome activity in the brainstem and
spinal cord of hSOD1
G93A transgenic mice at the symp-
tomatic stage.
Neuroinflammation occurs as a result of oxidative and
excitotoxic neuronal damage, mitochondrial dysfunction,
and protein aggregation [20]. Increased release of pro-
inflammatory cytokines, such as TNF-a and IL-6
induces microglia activation in spinal cord of
hSOD1
G93A mice [21]. Recently, we demonstrated that
BV attenuated neuroinflammation due to microglia acti-
vation and extended the life span of hSOD1
G93A trans-
genic mice. Consistent with previous reports, the
current study demonstrates that melittin, a 26-amino
acid polypeptide that is a component of BV, improved
motor activity (Figure 1) and reduced neuroinflamma-
tory events in the brainstem and spinal cord of sympto-
matic hSOD1
G93A mice (Figure 3). However, melittin
d i dn o te x t e n dt h es u r v i v a lt i m eo fh S O D 1
G93A mice
(Figure 2) even though melittin-treated hSOD1
G93A
mice delayed disease onset. These findings suggest that
anti-neuroinflammation mediated by melittin was not
sufficient to prolong lifespan in an ALS animal model.
Neuroinflammation may also be a direct response to
protein aggregation [22]. Therefore, it is believed that
drugs that modulate inflammation may combat disease
progression. The targeting of the different pathogenic
events associated with neurodegenerative diseases, such
as the clearance of disaggregated proteins, together with
neuroprotective and immunomodulatory strategies, may
be required for the effective treatment of these diseases.
Many diseases are associated with the expression of mis-
folded proteins that interfere with diverse cellular pro-
cesses. A number of neurodegenerative disorders,
including Parkinson’s disease (PD), ALS, Alzheimer’s
disease (AD), and polyglutamine diseases, are associated
with the chronic expression of specific disease-asso-
ciated proteins, resulting in the accumulation of mis-
folded species in brain tissue [23]. To protect from the
stress of misfolded proteins, all cells express cytoprotec-
tive machinery.
PD is the most prevalent neurodegenerative move-
ment disorder and is clinically characterized by rigidity,
akinesia, resting tremors, postural instability, and cogni-
tive impairment. PD is considered a synucleinopathy
due to the ubiquitous deposition of a-synuclein in the
central nervous system of PD patients, with a particu-
larly high enrichment in presynaptic termini, and the
associated specific synaptic pathology associated with a-
synuclein aggregations [24]. Because a-synuclein is
detected in both glial white matter and gray matter in
familial ALS patients [17], we investigated the effects of
melittin on a-synuclein in hSOD1
G93A mice. We
observed that a-synuclein phosphorylation and nitration
were increased in the brainstem and spinal cord of
symptomatic hSOD1
G93A transgenic mice and the
administration of melittin reduced changes in the post-
translation modification of a-synuclein in these tissues
(Figure 4A-C). Post-translational modification of a-
synuclein at Ser129 has been reported and is the most
intensely studied modification of this protein to date.
The relatively high abundance of this modified form of
a-synuclein in Lewy bodies, and the fact that this post-
translational modification occurs at low levels in the
absence of large protein aggregates [25], suggests that it
may promote aggregation. The phosphorylation of a-
synuclein at Ser129 may be a significant pathological
event because a-synuclein is not commonly phosphory-
lated at this site under physiological conditions [26].
Ser129 phosphorylation of a-synuclein was correlated
with pathological changes in Ab and tau in vivo [27]. In
this study, we demonstrated the co-localization of a-
synuclein and ubiquitin in motor neuron of the lumber
spinal cord in symptomatic hSOD1
G93A transgenic mice
(Figure 5). Furthermore, melittin treatment reduced sig-
nificantly ubiquitinated proteins in the brainstem and
the ventral horn of spinal cord in hSOD1
G93A (Figure
5). Based on these results and on those other previous
studies, we propose that the pathological mechanisms of
ALS and PD may be related and, therefore, that melittin
treatment may reduce neuroinflammation in PD. How-
ever, it should be determined whether melittin directly
affects cell toxicity caused PD-related other proteins in
the further study.
Various stressful stimuli cause unfolded or misfolded
proteins to accumulate within cells. Heat shock proteins
(HSPs) recognize misfolded proteins and aid in refold-
ing. In addition to their chaperone activity, HSPs have
been shown to facilitate the degradation of highly mis-
folded proteins by transferring them to the ubiquitin/
proteasome degradation system [28]. Gifondorwa et al.
hypothesized that the administration of HSP70 might
delay the progressive loss of motor neurons that has
been observed in ALS [29]. HSPs can protect neural
cells from various stresses, including oxidative stress
and excitotoxicity [30,31]. Furthermore, Batulan et al.
demonstrated an additional neuroprotective role for the
primary stress-inducible HSP70 in an animal model of
ALS [32]. Moreover, extracellular HSP70 has been
shown to play an important role in immune and inflam-
matory responses [33]. In this study, we found that
melittin administration caused an increased HSP70
expression in the brainstem and spinal cord of sympto-
matic hSOD1
G93A mice compared to the same tissues
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results suggest that melittin regulates the production of
misfolded proteins by activating chaperone proteins,
including HSP70 and by affecting phosphorylation path-
ways that could produce pathological proteins, such as
a-synuclein and tau in PD and AD.
To determine whether melittin affects protein degra-
dation, we investigated the role of the proteasome in the
brainstem and spinal cord of hSOD1
G93A mice. Consis-
tent with previous results, we observed an increase in
ubiquitinated proteins in the brainstem and spinal cord
of symptomatic hSOD1
G93A mice (Figure 5A, C).
Furthermore, melittin treatment decreased the levels of
ubiquitinated proteins in the brainstem and the anterior
horn of the spinal cord in hSOD1
G93A transgenic mice
(Figure 5B, D). The accumulation of misfolded proteins
into cellular aggregates is a prominent feature common
to most neurodegenerative diseases. These insoluble
proteinaceous deposits contain ubiquitin and compo-
nents of the ubiquitin/proteasome system, including
proteins encoded by genes mutated in familial cases (e.
g., the ubiquitin ligase parkin/PARK2) [34]. Alternations
in the ubiquitin/proteasome system, which are com-
monly observed in PD, can hinder the degradation of
aggregated a-synuclein [35]. In hSOD1
G93A mice, the
impairment of proteasome function caused by the
decreased solubility and aggregation of the mutant
SOD1 protein has been demonstrated by Kabahi et al.,
[36]. We observed a 1.8-fold reduction in proteasome
activity in the brainstem and spinal cord of symptomatic
hSOD1
G93A mice compared to age-matched non-trans-
genic mice (Figure 6A-B). Notably, melittin administra-
tion restored a 50% increase in proteasome activity in
the brainstem and a 40% increase in the lumbar spinal
cord (Figure 6B). Misfolded protein inclusions are a
common feature of several neurodegenerative disorders,
and their occurrence suggests the function of chaperone
protein and ubiquitin/proteasome pathways block to
degrade abnormal proteins [37,38].
Conclusions
The present work demonstrates that melittin reduces
neuroinflammatory events and induces a reduction in a-
synuclein modification via increased proteasome activity
in hSOD1
G93A mice, suggesting that proteasome activity
and chaperone proteins are responsible for the clearance
of the misfolded proteins, such as SOD1 and a-synu-
clein. The molecular and cellular mechanisms underly-
ing anti-neuroinflammation effects of melittin are not
entirely clear and remain to be further clarified by inten-
sive experimental studies. In addition, the link between
ALS and PD remains unclear. In further studies, addi-
tional experiments are needed to establish whether PD
and ALS share common pathological mechanisms and
the link between melittin and protein modification
remains to be established.
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